Literature DB >> 20832558

Outcomes of patients who develop symptomatic Clostridium difficile infection after solid organ transplantation.

O M Mitu-Pretorian1, B Forgacs, A Qumruddin, A Tavakoli, T Augustine, R Pararajasingam.   

Abstract

Clostridium difficile-associated diarrhea is the most common cause of hospital-associated diarrhea in the UK. Infection can produce a spectrum of manifestations from mild diarrhea to toxic megacolon, colonic perforation, and death. The aim of this study was to evaluate the outcomes of patients who developed symptomatic Clostridium difficile infection (CDI) within the first year after solid organ transplantation. Between 2004 and 2007, we performed 682 transplantation: 433 from deceased-donor kidney, 143 live-donor kidney, 18 pancreas-only, and 88 simultaneous kidney and pancreas transplants. Within the first year of transplantation, 24 patients developed symptomatic CDI. No single risk factor or antimicrobial agent was associated with acquiring infection. Among this group, 2 patients developed toxic megacolon requiring subtotal colectomy and recovered. Although 5 patients who developed CDI died within the first year, CDI was not the primary cause of death. The overall mortality of patients who developed CDI within the first year of transplantation accounted for 0.7% of all transplanted patients. Increased awareness of CDI and barrier nursing can minimize the impact of CDI on the morbidity and mortality associated with transplantation. Patients should be informed of the risk of CDI during consenting for transplantation, because the 3.5% incidence is more common than that of graft loss due to thrombosis. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832558     DOI: 10.1016/j.transproceed.2010.04.057

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries.

Authors:  Christian Eckmann; Matthew Wasserman; Faisal Latif; Graeme Roberts; Axelle Beriot-Mathiot
Journal:  Eur J Health Econ       Date:  2013-10

Review 2.  Clostridium difficile.

Authors:  Scott Curry
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

3.  Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients.

Authors:  Carolyn D Alonso; Mini Kamboj
Journal:  Curr Infect Dis Rep       Date:  2014-08       Impact factor: 3.725

4.  Outcomes of Clostridium difficile infection in recipients of solid abdominal organ transplants.

Authors:  Jennifer L Hsu; James J Enser; Trevor McKown; Glen E Leverson; John D Pirsch; Timothy M Hess; Nasia Safdar
Journal:  Clin Transplant       Date:  2014-01-30       Impact factor: 2.863

5.  Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.

Authors:  Mini Kamboj; Kun Xiao; Anna Kaltsas; Yao-Ting Huang; Janet Sun; Dick Chung; Saliangi Wu; Anna Sheahan; Kent Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-25       Impact factor: 5.742

6.  Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies.

Authors:  Suresh Paudel; Ioannis M Zacharioudakis; Fainareti N Zervou; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

7.  Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.

Authors:  Julie A K McDonald; Benjamin H Mullish; Alexandros Pechlivanis; Zhigang Liu; Jerusa Brignardello; Dina Kao; Elaine Holmes; Jia V Li; Thomas B Clarke; Mark R Thursz; Julian R Marchesi
Journal:  Gastroenterology       Date:  2018-07-17       Impact factor: 22.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.